- Coordinator
- Uniwersytet Im. Adama Mickiewicza Wpoznaniu, Poland
- Runs
- 1 January 2026 to 30 June 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101212992
What the project is doing
In the project's own words, from its summary on CORDIS.
Our value proposition is improving cancer therapy by identification of novel anti-cancer candidate drug leads modulating transcription termination, bridging molecular cancer biology and therapeutic applications. We have developed a methodology to directly measure alterations in transcription termination and successfully subjected it to miniaturization and automatization processes. We are applying for funding to validate a screening platform to identify small molecule inhibitors of transcription termination.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Uniwersytet Im. Adama Mickiewicza Wpoznaniu | Poznan | Poland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI